UNIT 9 MN 553 Pharm
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
Question options:
A need to monitor drugs metabolized by 2D6 for toxicity
Increased dosages needed of drugs metabolized by 2D6, such as the selective serotonin
reuptake inhibitors
Decreased conversion of codeine to morphine by CYP 2D6
The need for lowered dosages of drugs, such as beta blockers - ANSIncreased dosages
needed of drugs metabolized by 2D6, such as the selective serotonin reuptake inhibitors
Rifampin is a nonspecific CYP450 inducer that may:
Question options:
Lead to toxic levels of rifampin and must be monitored closely
Cause toxic levels of drugs, such as oral contraceptives, when coadministered
Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic failure
Cause nonspecific changes in drug metabolism - ANSInduce the metabolism of drugs, such as
oral contraceptives, leading to therapeutic failure
Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Question options:
Decreased therapeutic levels of quinidine
Increased therapeutic levels of quinidine
Decreased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for
absorption and elimination
Increased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for
absorption and elimination - ANSIncreased levels of a coadministered drug, such as digoxin,
that requires P-glycoprotein for absorption and elimination
Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
, Question options:
Toxic levels of warfarin building up
Decreased response to warfarin
Increased risk for significant drug interactions with warfarin
Less risk of drug interactions with warfarin - ANSDecreased response to warfarin
Pharmacogenetic testing is required by the U.S. Food and Drug Administration prior to
prescribing:
Question options:
Erythromycin
Digoxin
Cetuximab
Rifampin - ANSCetuximab
Carbamazepine has a Black Box Warning recommending testing for the HLA-B*1502 allele in
patients with Asian ancestry prior to starting therapy due to:
Question options:
Decreased effectiveness of carbamazepine in treating seizures in Asian patients with the
HLA-B*1502 allele
Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 Allele
Patients who have the HLA-B*1502 allele being more likely to have a resistance to
carbamazepine - ANSIncreased risk for Stevens-Johnson syndrome in Asian patients with
HLA-B*1502 Allele
A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by
the body may lead to:
Question options:
Decreased effectiveness of irinotecan in the treatment of cancer
Increased adverse drug reactions, such as neutropenia
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
Question options:
A need to monitor drugs metabolized by 2D6 for toxicity
Increased dosages needed of drugs metabolized by 2D6, such as the selective serotonin
reuptake inhibitors
Decreased conversion of codeine to morphine by CYP 2D6
The need for lowered dosages of drugs, such as beta blockers - ANSIncreased dosages
needed of drugs metabolized by 2D6, such as the selective serotonin reuptake inhibitors
Rifampin is a nonspecific CYP450 inducer that may:
Question options:
Lead to toxic levels of rifampin and must be monitored closely
Cause toxic levels of drugs, such as oral contraceptives, when coadministered
Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic failure
Cause nonspecific changes in drug metabolism - ANSInduce the metabolism of drugs, such as
oral contraceptives, leading to therapeutic failure
Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Question options:
Decreased therapeutic levels of quinidine
Increased therapeutic levels of quinidine
Decreased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for
absorption and elimination
Increased levels of a coadministered drug, such as digoxin, that requires P-glycoprotein for
absorption and elimination - ANSIncreased levels of a coadministered drug, such as digoxin,
that requires P-glycoprotein for absorption and elimination
Warfarin resistance may be seen in patients with VCORC1 mutation, leading to:
, Question options:
Toxic levels of warfarin building up
Decreased response to warfarin
Increased risk for significant drug interactions with warfarin
Less risk of drug interactions with warfarin - ANSDecreased response to warfarin
Pharmacogenetic testing is required by the U.S. Food and Drug Administration prior to
prescribing:
Question options:
Erythromycin
Digoxin
Cetuximab
Rifampin - ANSCetuximab
Carbamazepine has a Black Box Warning recommending testing for the HLA-B*1502 allele in
patients with Asian ancestry prior to starting therapy due to:
Question options:
Decreased effectiveness of carbamazepine in treating seizures in Asian patients with the
HLA-B*1502 allele
Increased risk for drug interactions in Asian patients with the HLA-B*1502 allele
Increased risk for Stevens-Johnson syndrome in Asian patients with HLA-B*1502 Allele
Patients who have the HLA-B*1502 allele being more likely to have a resistance to
carbamazepine - ANSIncreased risk for Stevens-Johnson syndrome in Asian patients with
HLA-B*1502 Allele
A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by
the body may lead to:
Question options:
Decreased effectiveness of irinotecan in the treatment of cancer
Increased adverse drug reactions, such as neutropenia
